Custom CRISPR infant treatment wins top clinical research prize

By AI, Created 3:38 PM UTC, May 18, 2026, /AGP/ – A landmark patient-specific gene-editing study led by Children’s Hospital of Philadelphia won the Clinical Research Forum’s top award in Washington, D.C., after showing a customized CRISPR therapy can treat a newborn with a severe metabolic disorder. The recognition underscores how personalized gene editing, lower-cost malaria prevention, and medication access research are shaping near-term clinical care.

Why it matters: - The award spotlights a first-in-kind treatment approach for a life-threatening newborn metabolic disorder. - The study adds evidence that patient-specific gene editing could move from experimental concept to real-world therapy for rare genetic diseases. - The annual awards are meant to show the return on investment in clinical research and its impact on health outcomes.

What happened: - The Clinical Research Forum gave its Herbert Pardes, MD Clinical Research Excellence Award to Dr. Rebecca Ahrens-Nicklas and her team at Children’s Hospital of Philadelphia. - The honored study used customized, in-body CRISPR gene editing to treat a newborn with severe neonatal-onset carbamoyl phosphate synthetase 1 deficiency. - The recognition came during the Forum’s annual Top 10 Clinical Research Achievement Awards on May 11 in Washington, D.C. - Dr. Rebecca Ahrens-Nicklas and her team also received a $7,500 cash prize.

The details: - The study was titled “Treatment of an Infant with Severe Neonatal-Onset Carbamoyl Phosphate Synthetase 1 Deficiency with a Personalized Gene-Editing Therapy.” - The Clinical Research Forum is a nonprofit membership association of clinical research experts and thought leaders from major academic health centers. - The Top 10 Awards recognize research advances that combine innovation with measurable impact on human disease. - A complete list of the 2026 Top 10 Award Winners is available on the Clinical Research Forum website. - Two other studies received Distinguished Clinical Research Achievement Awards and $5,000 each. - “Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries,” nominated by the University of Pennsylvania, found a measurable and statistically significant increase in mortality when low-income Medicare beneficiaries lost subsidized prescription drug coverage after disenrolling from Medicaid. - That study found the mortality increase was especially pronounced among people with chronic conditions that require consistent medication use. - “Permethrin-Treated Baby Wraps for the Prevention of Malaria,” nominated by the University of North Carolina at Chapel Hill, found that treating infant swaddling cloths with permethrin reduced malaria infections in babies. - The malaria study reported a two-thirds reduction in malaria cases among infants. - The intervention was described as simple, low cost and easily scalable. - The 2026 Top 10 awards included work from investigators at more than 60 research institutions and partner institutions around the world.

Between the lines: - The award choice signals growing momentum for personalized medicine, especially for rare diseases that have few treatment options. - The Medicare coverage study points to a broader policy lesson: access to affordable medicines can directly affect survival. - The malaria study shows how a low-tech intervention can have outsized impact in global child health. - Dr. Harry Selker, chair of the Clinical Research Forum, said the gene-editing breakthrough shows patient-specific gene editing can become reality and highlighted the child’s parents for agreeing to the experimental trial.

What’s next: - The recognition is likely to keep attention on personalized gene-editing therapies as researchers test whether the approach can be expanded to other rare genetic disorders. - The award winners may also influence future policy and funding discussions around drug coverage and low-cost disease prevention tools. - The Clinical Research Forum will continue using its annual awards to highlight high-impact clinical research advances.

The bottom line: - A single infant gene-editing case, a mortality study tied to drug access, and a low-cost malaria intervention all landed on the same stage, underscoring how clinical research can reshape care across very different settings.